Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 12:9:a25256768.
doi: 10.1055/a-2525-6768. eCollection 2025.

Assessment of the Haemostatic Potential of Platelets Readied for Transfusion

Affiliations

Assessment of the Haemostatic Potential of Platelets Readied for Transfusion

Unwana Emagha et al. TH Open. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Residual platelets in transfusion bags (<8 days old) were tested for response to agonists (maximum aggregation rate; MAR) using the Sinnowa PL-12 platelet function analyser. The agonists used were thrombin receptor-activating peptide (TRAP 32 μM, n  = 16), arachidonic acid (AA; 0.2 mg/mL, n  = 38), ADP (5 μM, n  = 38; 50 μM, n  = 16), and adrenaline (ADR; 100 μM, n  = 14).
Fig. 2
Fig. 2
Blood was collected from healthy volunteers and PRP was prepared from it ( n  = 6). Both the blood and corresponding PRP were stimulated with ADP (5 and 10 μM) and arachidonic acid (0.2 and 0.4 mg/mL). The response to agonist is presented as maximum aggregation rate (MAR).
Fig. 3
Fig. 3
Blood was collected from healthy volunteers and PRP was prepared ( n  = 6) and stored at room temperature for 72 hours. PRP was stimulated with agonist immediately after preparing PRP ( t  = 0) and over 72 hours. Aggregation response is presented as maximum aggregation rate (MAR). ( A ) PRP stimulated with 5, 10, and 20 μM ADP. ( B ) PRP stimulated with 0.2. 0.4, and 0.8 mg/mL arachidonic acid.

Similar articles

References

    1. Banerjee S, Angiolillo D J, Boden W E et al.Use of antiplatelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery. J Am Coll Cardiol. 2017;69(14):1861–1870. - PubMed
    1. Shpigelman J, Proshkina A, Daly M J, Cox D. Personalized dual antiplatelet therapy in acute coronary syndromes: striking a balance between bleeding and thrombosis. Curr Cardiol Rep. 2023;25(07):693–710. - PMC - PubMed
    1. Taylor G, Osinski D, Thevenin A, Devys J-M. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg. 2013;74(05):1367–1369. - PubMed
    1. Cohn S M, Jimenez J C, Khoury L, Perez J M, Panzo M. Inability to reverse aspirin and clopidogrel-induced platelet dysfunction with platelet infusion. Cureus. 2019;11(01):e3889. - PMC - PubMed
    1. Nagalla S, Sarode R. Role of platelet transfusion in the reversal of anti-platelet therapy. Transfus Med Rev. 2019;33(02):92–97. - PubMed

LinkOut - more resources